Index reshuffle puts Zoetis in the midcap spotlight

Zoetis (ZTS) is back in focus after being added to the Russell Midcap Index and related style benchmarks, while simultaneously exiting several Russell Top 200 indices. This shift can influence index-tracking fund flows.

This reclassification follows a period where Zoetis shares declined 2% over the past month and roughly 36% over the past 3 months, leaving the stock down about 40% year to date and roughly 50% over the past year.

At a share price of $76.09, Zoetis has seen momentum fade, with the 90 day share price return down 35.63% and the 1 year total shareholder return down 50.45%. The latest index reshuffle has focused attention on how investors are reassessing its risk and growth profile.

If Zoetis's index move has you rethinking where growth might come from next, it could be worth scanning other healthcare AI opportunities through the 40 healthcare AI stocks

With Zoetis now trading well below many analyst valuation markers after a sharp share price reset, the key question is whether investors are looking at a discounted entry point or a stock where the market already prices in future growth.

Most Popular Narrative: 18.1% Undervalued

At $76.09, the most followed narrative on Zoetis from ValueInvestingSubstack pegs fair value at $92.92, implying a material gap between price and narrative valuation built on steady earnings and cash flows.

On one hand it’s not a business that’s going to grow much; on the other hand, it’s also not likely to collapse catastrophically. Double-edged sword. The company cites generics as a potential risk in its financial statements. I’m not sure how much of this could be attributable to the 11% YoY decline in Pet segment revenues, but this is just something to watch out for if you’re interested in investing in the business.

Want to see what turns this cautious tone into an 18.1% undervaluation call? The narrative leans heavily on earnings resilience, margin strength, and a specific profit multiple that sits well above where Zoetis trades today, without assuming breakneck growth.

Result: Fair Value of $92.92 (UNDERVALUED)

However, investors still need to watch for a deeper or prolonged decline in the US Companion Animal segment, as well as any acceleration in generic competition that pressures Zoetis margins.

Next Steps

If the mixed tone around Zoetis leaves you unsure which way sentiment truly leans, move quickly to review the full picture and form your own view with the 5 key rewards and 1 important warning sign

Looking for more investment ideas beyond Zoetis?

If Zoetis has sharpened your focus on quality and valuation, do not stop here. Broaden your watchlist with a few targeted stock ideas that fit clear, disciplined themes.

• Target potential mispricings by scanning for companies that combine strong fundamentals with attractive valuations through the 44 high quality undervalued stocks
• Strengthen your portfolio foundation by focusing on companies with healthier finances using the solid balance sheet and fundamentals stocks screener (48 results)
• Unearth earlier stage opportunities that the market may be overlooking by checking the screener containing 19 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.